Arcus Biosciences, Inc. reports developments as a clinical-stage global biopharmaceutical company developing differentiated molecules and combination therapies for cancer and inflammatory and autoimmune diseases. Company news commonly covers quarterly financial results, pipeline updates, clinical program strategy, data presentations and changes in research priorities across its investigational portfolio.
Recurring updates focus on casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer, and earlier inflammation programs such as AB102, an MRGPRX2 antagonist. Arcus also issues routine corporate announcements on employment inducement grants, investor conference participation and collaboration-related developments.
Arcus Biosciences (NYSE:RCUS) reported a third-quarter 2026 net loss of $128 million and outlined upcoming casdatifan clinical trial milestones. Revenue fell to $9 million from $26 million a year earlier; net loss narrowed from $135 million. Cash and marketable securities totaled $694 million at September 30, versus $1,010 million at December 31, 2025. Including $288 million in gross October equity financing proceeds, Arcus expects funding into 2029.
Arcus expects PEAK-1 enrollment to finish in two to three months and first-line kidney cancer trial PEAK-20 to begin by year-end 2026. ARC-20 results included median progression-free survival of 14.5 months with casdatifan plus cabozantinib in second-line treatment and median overall survival of 35 months with late-line casdatifan monotherapy. More data are expected in 2027. An interim analysis of the Phase 3 pancreatic cancer trial PRISM-1 is scheduled for the fourth quarter of 2026.
Arcus Biosciences (NYSE:RCUS) announced that its management team will join a fireside chat at the Jefferies Global Healthcare Conference on November 16, 2026.
The chat in London, UK, is scheduled for 5:00pm GMT. A live webcast will be available through the Investors & Media section of www.arcusbio.com, with a replay available after the event.
Arcus Biosciences (RCUS) granted stock options and restricted stock units to three new employees through its employment inducement plan.
The options cover 10,650 common shares at an exercise price of $18.54 per share, matching the closing price on October 23, 2026. The restricted stock units cover another 5,350 common shares. The Compensation Committee approved the awards under the 2020 Inducement Plan, which the board approved in January 2020 under the NYSE employment inducement exception.
Arcus Biosciences (NYSE: RCUS) priced an underwritten public offering of its common stock, with expected gross proceeds of $250.0 million.
The company is offering 14,285,715 shares at $17.50 per share. Expected proceeds are before underwriting discounts, commissions and offering expenses. Underwriters also received a 30-day option to purchase up to 2,142,857 additional shares at the public offering price, less underwriting discounts and commissions. Arcus expects the offering to close on October 23, 2026, subject to customary closing conditions.
Arcus Biosciences (NYSE: RCUS) has commenced an underwritten public offering of common stock, with all shares offered by the company.
Arcus intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares offered. Completion, timing, size and terms remain uncertain, and the offering is subject to market and other conditions. Jefferies, Leerink Partners and TD Cowen are acting as joint book-running managers.
Arcus Biosciences (RCUS) reported new ARC-20 kidney cancer data for investigational casdatifan across first-line, second-line and later treatment settings. First-line casdatifan plus zimberelimab produced 86% and 69% progression-free survival at six and 12 months in 30 patients, with a 50% confirmed response rate. Second-line casdatifan plus cabozantinib achieved median progression-free survival of 14.5 months in 43 patients, versus approximately 10 months in external cabozantinib benchmarks. Pooled late-line monotherapy cohorts covering 121 patients showed 35-month median overall survival, 13-month median progression-free survival and a 36% confirmed response rate.
Arcus expects the first-line Phase 3 PEAK-20 trial to start in the fourth quarter of 2026. Phase 3 PEAK-1 is ongoing in second-line treatment, and Arcus plans a registrational trial of casdatifan plus tivozanib versus tivozanib. All cohorts used a September 4, 2026 data cutoff.
Arcus Biosciences (RCUS) announced equity inducement awards to two new employees, including options to purchase 9,150 common shares.
The Compensation Committee also granted restricted stock units to acquire 4,600 common shares. The options have an exercise price of $23.83 per share, matching the closing price on October 8, 2026. Both awards were granted under the company's 2020 Inducement Plan, approved by its board in January 2020 under the inducement exception in NYSE Rule 303A.08.
Arcus Biosciences (RCUS) granted equity awards to four new employees on September 24, 2026, under its 2020 Inducement Plan.
The awards comprise options to purchase a total of 21,200 shares at $26.39 per share and restricted stock units to acquire a total of 10,650 shares. The option exercise price was the stock’s closing price on September 23, 2026. The board approved the plan in January 2020 under the inducement exception to a NYSE listing rule.
Arcus Biosciences (RCUS) will host an in-person investor event with live webcast on October 20, 2026, at 8:30 AM ET in New York City to present new ARC-20 study data for casdatifan in clear cell renal cell carcinoma across first-, second- and late-line settings.
Presentations will cover casdatifan combinations with zimberelimab and ipilimumab as first-line TKI-free regimens, a second-line TKI-containing combination with cabozantinib, and late-line monotherapy, including safety, overall response rate, progression-free survival and overall survival readouts. Data are intended to inform and support registrational trials PEAK-20 and PEAK-1, as well as Arcus's strategy to position casdatifan as a backbone therapy in ccRCC.
Arcus Biosciences (RCUS) granted equity inducement awards to one new employee under its 2020 Inducement Plan. The awards consist of options to purchase 26,350 shares of common stock at an exercise price of $29.06 per share, equal to the closing price on September 8, 2026, and restricted stock units covering 13,200 shares of common stock.
The grants were approved by the Compensation Committee of the Board of Directors and made pursuant to the company’s 2020 Inducement Plan, which was approved in January 2020 under the NYSE Listed Company Manual Rule 303A.08 “inducement exception.”